ER-negative breast tumours: Aberrant p53 and ORFP1 expression analysis
Research type
Research Study
Full title
To investigate the correlation between ER in breast cancers and expression of p53 and ORFP1: An immunohistochemical analysis.
IRAS ID
347244
Contact name
Phuoc-Tan Diep
Contact email
Sponsor organisation
Morecambe Hospitals NHS Trust
Duration of Study in the UK
0 years, 7 months, 1 days
Research summary
This research aims to understand why certain breast cancers, known as oestrogen receptor (ER)-negative tumours, behave more aggressively than others. We will be looking at two proteins, p53 and ORFP1, which might play a role in this aggressive behaviour. With the use of breast cancer tissue samples we can examine this by using a technique called immunohistochemistry to detect and measure these proteins. This method involves using special markers that make the proteins visible under a microscope. Our goal is to see if there is a significant difference in the levels of these proteins between ER-negative and ER-positive breast cancers. Understanding these differences could help in developing better diagnostic tools and treatments for breast cancer in the future.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
25/NW/0201
Date of REC Opinion
15 Jul 2025
REC opinion
Favourable Opinion